Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioGaia ABBGLAF 100 3-Year EPS without NRI Growth Rate is 3.30% as of Jun. 2026, which is 76% below its 10-year median of 13.95. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.07 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 788 Drug Manufacturers companies, BioGaia AB ranks worse than 59.52% on this metric.
During the past 12 months, BioGaia AB's average EPS without NRI Growth Rate was 21.20% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 3.30% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 13.90% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 7.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of BioGaia AB was 135.50% per year. The lowest was -40.50% per year. And the median was 13.95% per year.
BioGaia AB (OTCPK:BGLAF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
BioGaia AB 3-Year EPS without NRI Growth Rate Related Terms
BGLAF vs ZTS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where BioGaia AB's 3-Year EPS without NRI Growth Rate falls into.
BioGaia AB 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 3.30% mean?
BioGaia AB (BGLAF) has a 3-Year EPS without NRI Growth Rate of 3.30% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for BioGaia AB and its competitors. This is 76% below median its historical median of 13.95. According to the industry distribution chart, BioGaia AB ranks #469 out of 788 companies in the Drug Manufacturers industry, placing it in the top 59.5%.
Is BioGaia AB's 3-Year EPS without NRI Growth Rate too high?
BioGaia AB's current 3-Year EPS without NRI Growth Rate of 3.30% is 76% below median its 10-year median of 13.95. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.65. BioGaia AB's value of 3.30% is 65.8% below this industry median. Based on the distribution chart, BioGaia AB ranks #469 out of 788 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, BioGaia AB has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's 3-Year EPS without NRI Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #469 out of 788 companies for 3-Year EPS without NRI Growth Rate. This places BioGaia AB in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.65. BioGaia AB's value of 3.30% is 65.8% below this benchmark. While the company's 10-year median is 13.95 vs. the industry median of 9.65, BioGaia AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.65, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current 3-Year EPS without NRI Growth Rate of 3.30% is 65.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for BioGaia AB and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current 3-Year EPS without NRI Growth Rate is 3.30%, which is 76% below median its own 10-year median of 13.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
Based on GuruFocus' analysis, BioGaia AB (BGLAF) is currently considered Modestly Undervalued. The stock's GF Value™ is $13.07, compared to a current price of $11.55 — trading 11.6% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 3.30%, which is 76% below median its 10-year median of 13.95 and 65.8% below the Drug Manufacturers industry median of 9.65. BioGaia AB's overall GF Score™ is 100/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current 3-Year EPS without NRI Growth Rate is 3.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $11.55 is trading 11.6% below its estimated GF Value™ of $13.07.
GuruFocus considers BioGaia AB to be Modestly Undervalued.
Key valuation signals for BGLAF:
3-Year EPS without NRI Growth Rate: 3.30% (76% below median its 10-year median of 13.95)
GF Value™: $13.07 vs. price of $11.55 (11.6% below fair value)
Industry Position: 65.8% below the Drug Manufacturers median (#469 of 788)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
